Tag: AI in biotech
-
All In on Biosim AI with Simulations Plus
Overview: A New Era for Biosimilars The conversation around biosimilars is shifting from incremental improvements to rapid, AI-powered discovery and validation. In this era, Biosim AI—driven by advanced simulations and pharmacometric tools—offers a path to faster timelines, improved predictability, and greater confidence for regulators, manufacturers, and patients. A recent discussion hosted by TD Cowen Insights…
-
Galux and Boehringer Ingelheim Partner on AI Protein Design
Galux Collaborates with Boehringer Ingelheim to accelerate AI-driven protein design South Korea’s Galux, a biotech startup focused on AI-powered protein therapeutics discovery, has entered a strategic research agreement with Boehringer Ingelheim. The collaboration aims to explore and advance artificial intelligence technologies that can design novel protein therapeutics with improved efficacy, safety, and development timelines. The…
-
Galux and Boehringer Ingelheim Forge AI-Driven Protein Design Partnership
Overview of the Collaboration Galux, a South Korean biotechnology company pioneering artificial intelligence in protein therapeutics discovery, has announced a research agreement with Boehringer Ingelheim. The collaboration aims to explore and advance AI-driven protein design to accelerate the development of novel biologics and peptide therapies. This partnership reflects a broader industry shift toward leveraging advanced…
-
CancerVax Precision Therapy Shows Promise in Reducing Liver Toxicity
Overview: A New Approach to Universal Cancer Therapy CancerVax, Inc. has announced promising in-vitro findings for its universal cancer treatment platform, a pioneering approach that leverages the body’s immune system to target and kill cancer cells. The company reports that its nanotechnology-based therapy dramatically reduces liver toxicity, a major hurdle for many cancer drugs, by…
-
CancerVax Precision Therapy Delivers Safer Cancer Treatment with Liver-Sparing Promise
Introduction: A Breakthrough in Universal Cancer Therapy CancerVax, Inc. announces a promising advance in its universal cancer treatment platform, designed to harness the body’s immune system to attack cancer cells with unprecedented precision. In vitro studies indicate that this approach dramatically reduces liver toxicity, a long-standing obstacle in cancer drug development. By combining a two-step…